PURPOSE: To assess the risk of interstitial lung disease (ILD) with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib, erlotinib, and afatinib. METHOD: PubMed databases were searched for relevant articles. Statistical analyses were conducted to calculate the summary incidence, odds ratio (OR), and 95% confidence intervals (CIs) by using either random-effects or fixed-effect models. RESULTS: The incidence of all-grade and high-grade (≧ grade 3) ILD associated with EGFR-TKIs was 1.6% (95% CI, 1.0-2.4%) and 0.9% (95% CI, 0.6%-1.4%), with a mortality of 13.0% (95% CI, 7.6-21.6%). Patients treated with EGFR-TKIs had a significantly increased risk of developing all-grade (OR, 1.74; 95% CI, 1.25-2.43; P = 0.001) and high-grade (OR, 4.38; 95% CI, 2.18-8.79; P<0.001) ILD. No significant difference in the risk of ILD was found in sub-group analysis according to EGFR-TKIs, percentage of EGFR mutation, study location, EGFR-TKIs-based regimens, and controlled therapy. CONCLUSIONS: Treatment with EGFR-TKIs is associated with a significantly increased risk of developing ILD.
PURPOSE: To assess the risk of interstitial lung disease (ILD) with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib, erlotinib, and afatinib. METHOD: PubMed databases were searched for relevant articles. Statistical analyses were conducted to calculate the summary incidence, odds ratio (OR), and 95% confidence intervals (CIs) by using either random-effects or fixed-effect models. RESULTS: The incidence of all-grade and high-grade (≧ grade 3) ILD associated with EGFR-TKIs was 1.6% (95% CI, 1.0-2.4%) and 0.9% (95% CI, 0.6%-1.4%), with a mortality of 13.0% (95% CI, 7.6-21.6%). Patients treated with EGFR-TKIs had a significantly increased risk of developing all-grade (OR, 1.74; 95% CI, 1.25-2.43; P = 0.001) and high-grade (OR, 4.38; 95% CI, 2.18-8.79; P<0.001) ILD. No significant difference in the risk of ILD was found in sub-group analysis according to EGFR-TKIs, percentage of EGFR mutation, study location, EGFR-TKIs-based regimens, and controlled therapy. CONCLUSIONS: Treatment with EGFR-TKIs is associated with a significantly increased risk of developing ILD.
Authors: N Jewel Samadder; Scott K Kuwada; Kenneth M Boucher; Kathryn Byrne; Priyanka Kanth; Wade Samowitz; David Jones; Sean V Tavtigian; Michelle Westover; Therese Berry; Kory Jasperson; Lisa Pappas; Laurel Smith; Danielle Sample; Randall W Burt; Deborah W Neklason Journal: JAMA Oncol Date: 2018-05-01 Impact factor: 31.777
Authors: N Jewel Samadder; Deborah W Neklason; Kenneth M Boucher; Kathryn R Byrne; Priyanka Kanth; Wade Samowitz; David Jones; Sean V Tavtigian; Michelle W Done; Therese Berry; Kory Jasperson; Lisa Pappas; Laurel Smith; Danielle Sample; Rian Davis; Matthew K Topham; Patrick Lynch; Elena Strait; Wendy McKinnon; Randall W Burt; Scott K Kuwada Journal: JAMA Date: 2016 Mar 22-29 Impact factor: 56.272
Authors: Ahmet M Ulusan; Praveen Rajendran; Wan Mohaiza Dashwood; Omer F Yavuz; Sabeeta Kapoor; Trace A Gustafson; Michelle I Savage; Powel H Brown; Shizuko Sei; Altaf Mohammed; Eduardo Vilar; Roderick H Dashwood Journal: Cancer Prev Res (Phila) Date: 2020-12-04
Authors: Sang Hoon Yoo; Jin Ah Ryu; Seo Ree Kim; Su Yun Oh; Gu Sung Jung; Dong Jae Lee; Bong Gyu Kwak; Yu Hyun Nam; Kyung Hyun Kim; Young Jun Yang Journal: Korean J Fam Med Date: 2016-11-18
Authors: Jian-Guo Zhou; Xu Tian; Long Cheng; Quan Zhou; Yuan Liu; Yu Zhang; Yu-Ju Bai; Hu Ma Journal: Medicine (Baltimore) Date: 2015-10 Impact factor: 1.817